Investor Presentaiton

Growth Strategies and Plans 1 Continue to strengthen leadership positions in key business segments JUBILANT LIFESCIENCES 2 Radiopharma: Achieve market leadership by leveraging leadership in existing products and broad distribution network along with expansion of our product portfolio through launch of niche and differentiated products Allergy: Continue to drive growth and profitability through our strong customer commitment to be the partner-of-choice in the US allergy market and leveraging the strong brand recognition of the "HollisterStier" brand CMO: Strengthen industry position through "first time right" customer service and identifying new customer targets for ampoules, semi-solids and non-sterile liquids APIs: Focused on product selection and cost optimization, to continue to be a preferred supplier to our customers Formulations: Focus on cost leadership with increased integration in our portfolio mix and of in-house APIs and continue to expand our business into emerging markets by leveraging our existing US filings. ■ Life Science Chemicals Acetyls: Expand our market share globally of Acetic Anhydride by expanding capacities and maximize Ethyl Acetate profitability through customer and market prioritization Ethanol: Expand our presence and market share of Ethanol to OMCs in domestic market Specialty Intermediates Retain top 2 global position in Pyridine & Picolines business " New products development and launch to improve ROCE of FI & CSI business ◉ Expand CDMO business offering products from cGMP facilities to global Pharma Innovator customers Nutritional Products Retain top 2 global position in Vitamin B3 with focus on feed, human nutrition and personal care industries; Expand Niacin business also Expand & Retain ledership position in Vit B4 (Choline Chloride) in domestic market. Expand Animal and Human Nutrition product portfolio Be closer to the customer to provide high quality products and services Current Platform: Approximately 70% of our assets are in North America which account for 80% total revenue from operations (Pharma Segment) ➤ Targets: Leverage the insights gained from successfully bringing products in North American market to launch products in other markets JUBILANT LIFESCIENCES

View entire presentation